Boston Scientific Corporation $BSX Shares Purchased by Nomura Asset Management Co. Ltd.

31 May 2026, 08:22 by Amy Steele · The Cerbat Gem

Nomura Asset Management Co. Ltd. increased its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 3.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 906,900 shares of the medical equipment provider’s stock after purchasing an additional 26,655 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Boston Scientific were worth $86,473,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares in the last quarter. Rathbones Group PLC raised its position in shares of Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares in the last quarter. Tounjian Advisory Partners LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at approximately $1,477,000. Kepler Cheuvreux Suisse SA acquired a new position in shares of Boston Scientific in the 3rd quarter valued at approximately $26,955,000. Finally, Waycross Partners LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at approximately $2,384,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of BSX opened at $48.32 on Friday. The company has a market cap of $71.82 billion, a P/E ratio of 20.22, a PEG ratio of 0.89 and a beta of 0.62. The stock has a fifty day moving average price of $60.23 and a 200 day moving average price of $78.62. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 12 month low of $48.13 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In related news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares in the company, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David C. Habiger acquired 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 9,800 shares of company stock worth $554,012 in the last three months. 0.34% of the stock is owned by insiders.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight/hold and lowered its outlook on the stock, citing rising uncertainty around the company’s electrophysiology business and WATCHMAN growth. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
Negative Sentiment: Reuters reported Boston Scientific hit a two-year low after flagging weaker demand for its WATCHMAN heart device, adding to investor concern that a core growth driver is slowing. Boston Scientific hits two-year low after flagging weaker demand for heart device
Negative Sentiment: The company’s 2026 guidance was reiterated, but investors viewed it as underwhelming given the slowdown in WATCHMAN and softer urology demand, which hurt sentiment further. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
Negative Sentiment: Analyst commentary from Zacks said Boston Scientific and Abbott both posted solid growth, but Boston Scientific is facing mounting operational pressures, which may be limiting upside near term. BSX vs. ABT: Which Medical Stock Has More Upside Potential?
Positive Sentiment: Despite the selloff, Boston Scientific’s clinical pipeline remains active, with updates on the FARAPULSE PFA atrial fibrillation study and a painful diabetic neuropathy trial milestone that could support future growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation Boston Scientific Nears Key Data Milestone in Painful Diabetic Neuropathy Trial
Positive Sentiment: Unusually large call-option buying suggests some traders are positioning for a rebound in BSX after the recent weakness. Investors Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Analyst Upgrades and Downgrades

BSX has been the topic of a number of recent analyst reports. National Bank Financial set a $115.00 target price on Boston Scientific in a research report on Monday, February 2nd. Oppenheimer set a $90.00 target price on Boston Scientific in a research report on Thursday, April 23rd. Barclays cut their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday. Morgan Stanley cut their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Leerink Partners cut their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.46.

Get Our Latest Stock Report on Boston Scientific

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.